international outcomes registries. COR's responsibilities include
maintaining patient and physician confidentiality, design of data
collection instruments, data management and publication
development.
Established in 1994, COR is an outgrowth of the Worcester Deep
Vein Thrombosis Study, a five-year NIH-supported program, which
demonstrated that physicians are more likely to improve patient
management practices if they are provided with valid data on their
own practices and outcomes along with regional and national
benchmarks.
About the University of Massachusetts Medical School
The University of Massachusetts Medical School, one of the
fastest growing academic health centers in the country, has built a
reputation as a world-class research institution, consistently
producing noteworthy advances in clinical and basic research. The
Medical School attracts more than US$174 million in research
funding annually, 80 percent of which comes from federal funding
sources. For more information, visit www.umassmed.edu.
ENDORSE study funding
The Center for Outcomes Research (COR) at the University of
Massachusetts Medical School received an unrestricted grant from
sanofi-aventis to support this work.
References
1. Goldhaber SZ, Tapson VF. Am J Cardiol. 2004;93:259-62.
2. Anderson FA Jr, et al. Blood. 2003;102 [abstract 1146].
3. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous
thromboembolism: the seventh ACCP conference on Antithrombotic and
Thrombotic Therapy. Chest. 2004;126:338S-400S.
CONTACT: Media Contact: Alison M. Duffy, Public Affairs and
Publications,+1-508-856-2000, alison.duffy@umassmed.edu
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
'"/>Page: 1 2 3 4 Related medicine technology :1.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis2.
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis3.
Inspiration Biopharmaceuticals Presents Data From Hemophilia
Program at International Society On Thrombosis and Haemostasis
(ISTH) Annual Meeting4.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis5.
Suven Life Sciences Presenting Pre-clinical data of their
NCE’s SUVN-502 and SUVN-507at International Brain Research
Organization (IBRO) 2007 World Congress of Neuroscience6.
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst
Congress of the International Society on Thrombosis and Haemostasis7.
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)8.
Labopharm to Present Poster on Dose Titration of Once-daily
Tramadol at 3rd International Forum on Pain Medicine9.
The European Myeloma Platform Reports New Survival data for
Revlimid Presented at the International Myeloma Workshop in Greece10.
The International Myeloma Foundation Says Data Reported at a Global
Medical Meeting in Greece Demonstrates Improved Survival for a Wide
Range of Myeloma Patients11.
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data
Presented at International Myeloma Workshop